Edition:
United Kingdom

BeyondSpring Inc (BYSI.OQ)

BYSI.OQ on NASDAQ Stock Exchange Capital Market

31.00USD
14 Dec 2017
Change (% chg)

$0.13 (+0.42%)
Prev Close
$30.87
Open
$30.93
Day's High
$31.00
Day's Low
$30.93
Volume
130
Avg. Vol
991
52-wk High
$48.42
52-wk Low
$16.65

Latest Key Developments (Source: Significant Developments)

BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Beyondspring Inc ::BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN).BEYONDSPRING INC - INTERIM ANTI-CANCER EFFICACY DATA FROM PHASE 3 NSCLC CLINICAL TRIAL IS EXPECTED IN MID-2018.  Full Article

Beyondspring Says Initiates Global Phase 2/3 Trial With Plinabulin In China
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Beyondspring Inc ::BEYONDSPRING INITIATES GLOBAL PHASE 2/3 TRIAL WITH PLINABULIN IN CHINA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA TO DEMONSTRATE SUPERIORITY.BEYONDSPRING INC - ‍EXPECT CFDA FILINGS OF FIRST NDAS FOR BOTH CIN AND NSCLC INDICATIONS POTENTIALLY IN 2018​.  Full Article

BeyondSpring qtrly loss per share $‍0.68
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - BeyondSpring Inc :BeyondSpring reports third quarter 2017 operational and financial results.BeyondSpring Inc - qtrly loss per share $‍0.68​.  Full Article

BeyondSpring announces first patient enrolled in China
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - BeyondSpring Inc ::BeyondSpring announces the first patient enrolled in China in its global phase 2/3 trial with plinabulin for the prevention of chemotherapy-induced neutropenia.BeyondSpring-‍look forward to top line results, later in 2017, comparing plinabulin with pegfilgrastim from phase 2 portion of the phase 2/3 trial.  Full Article

BeyondSpring Q1 loss per share $2.66
Monday, 22 May 2017 

May 22 (Reuters) - BeyondSpring Inc :Beyondspring reports first quarter 2017 financial results.Beyondspring inc qtrly basic and diluted loss per share of $2.66.Beyondspring inc - cash and cash equivalents were $54.6 million as of march 31, 2017, compared to $11.7 million as of december 31, 2016.  Full Article

BRIEF-BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin

* BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN)